Fundraising FoxPano Therapeautics
1 known investors
Find your way into Pano Therapeautics
Sign up to see every warm intro you have to Pano Therapeautics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pano Therapeautics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
Founders & leadership
Investors · 1
Western Technology Investmentlisted by Western Technology InvestmentPortola Valley
How we know: Western Technology Investment's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 2
PalvellatxPalvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Companies working in the same space as Pano Therapeautics.
Frequently asked questions
- What does Pano Therapeautics do?
- Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.
- Who founded Pano Therapeautics?
- Pano Therapeautics was founded by Ben Gibson, Ken Batchelor.
- Who are Pano Therapeautics's investors?
- Pano Therapeautics's investors include Western Technology Investment.